1865-11-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Quinoxalinecarboxylic acid methyl ester is used as a reactant for synthesizing quinoxaline derivatives with antimycobacterial activity. Although it displays minor activity itself, its role in creating more potent derivatives is significant.
Used in Antitumor Applications:
2-Quinoxalinecarboxylic acid methyl ester is used as a building block in the development of antitumor agents due to its substructure that exhibits antitumor activity. Its incorporation into various chemical structures can lead to the discovery of new and effective cancer treatments.
Used in DNA Cleaving Agents Design:
2-Quinoxalinecarboxylic acid methyl ester is utilized in the design of guanine-guanine selective DNA cleaving agents. Its unique properties allow for the creation of molecules that can specifically target and cleave DNA at guanine-guanine sites, which can have applications in genetic research and medicine.

Upstream product

• 110490-03-4 quinoxaline-2,3-dicarboxylic acid monomethyl ester 
• 67-56-1 methanol 
• 54745-92-5 quinoxaline-2-carboxylic acid chloride 
• 5660-34-4 quinoxaline-2,3-dicarboxylic acid anhydride 
• 879-65-2 quinoxaline-2-carboxylic acid 
• 1593-08-4 Quinoxaline-2-carboxaldehyde 
• 74200-25-2 Methyl Quinoxaline-3-carboxylate 1-Oxide 
• 494-21-3 2-furan-2-yl-quinoxaline 
• 1448-87-9 2-chloroquinoxaline 
• 819868-68-3 (4,5-dichloro-imidazol-1-yl)-quinoxalin-2-yl-acetonitrile 
• 819868-69-4 quinoxalin-2-yl-[1,2,4]triazol-1-yl-acetonitrile 
• 74-88-4 methyl iodide 
• 480-96-6 benzofurazan oxide 
• 2605-68-7 methyl 2-(triphenylphosphoranylidene)propionate 

Downstream Products

• 54571-06-1 quinoxaline-2-carbohydrazide 
• 108047-48-9 6,7-dimethyl-furazano<3,4-b>quinoxaline 
• 108047-51-4 diethyl 7,8-dimethyl-pyrazino<2,3-b>quinoxaline-2,3-dicarboxylate 
• 791-28-6 Triphenylphosphine oxide 
• 7065-23-8 ethyl quinoxaline-2-carboxylate 

Relevant academic research and scientific papers

Smaller is smarter in a new cobalt(II) imide: Intermolecular interactions involving pyrazine versus the larger aromatic quinoxaline

The synthesis of one symmetric and one non-symmetric ligand based on imide, quinoxaline and pyrazine moieties are reported. The symmetric ligand, N-(2-quinoxalylcarbonyl)-2-quinoxalinecarboxamide (Hquinoxquinox), is structurally characterised as Hquinoxquinox·d6DMSO. The non-symmetric ligand, N-(2-pyrazylcarbonyl)-2-quinoxalinecarboxamide (HLquinoxpz), was used to prepare the cobalt(II) complex [CoII(quinoxpz)2]·CH3OH, which was observed to remain high spin at 90 K. The structures of HLquinoxquinox·d6DMSO and [CoII(quinoxpz)2]·CH3OH are evaluated with regard to their potential to produce spin crossover (SCO) behaviour and for the construction of three-dimensional coordination polymers.

Azole-N-acetonitriles as carbonyl synthons: A one-pot preparation of heteroaryl amides from halides

Azole-N-acetonitrile derivatives were utilized as synthons for an ambident carbonyl moiety via a strategy relying upon sequential base-mediated S NAr substitution of a 2-halo heterocycle, in situ oxidation, and amine displacement. This strategy allows prompt and efficient synthesis of N-containing heteroaryl amides directly from the corresponding halides via a one-pot process.

Sodium cyanoborohydride-mediated direct conversion of some heterocyclic aldehydes to esters

An exceptional oxidizing behavior of sodium cyanoborohydride is observed where electron-withdrawing heterocyclic aldehydes are directly converted to their corresponding esters on treatment of sodium cyanoborohydride in methanol. The spectral analysis and

Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives

A series of pyrazine and quinoxaline derivatives have been synthesized, and their activity against M. tuberculosis (Mtb) and Mycobacterium avium (MAC) are reported. The 4-acetoxy-benzyl ester of pyrazinoic acid and 4′-acetoxybenzyl 2-quinoxalinecarboxylate showed excellent activity against Mtb (MIC ranges of less than 1-6.25 μg/mL) but only modest activity against MAC (MICs of 4-32 μg/mL).

First catalytic asymmetric hydrogenation of quinoxaline-2-carboxylates

For the first time, the asymmetric hydrogenation of quinoxaline-2-carboxylates was performed successfully. The best catalysts are based on iridium complexes modified by chiral phosphorous ligands. Accelerated examination of ligands and catalysts has been undertaken by using a Chemspeed workstation, which enables carrying out, in parallel, eight independent catalytic reactions at the laboratory scale. Tetrahydroquinoxaline-2-carboxylates could be obtained with high yields and up to 74% ee.

One-step direct conversion of heterocyelie aldehydes to esters

One-step direct conversion of a series of heteroeyelie aldehydes to heterocyclie esters is reported here by the use of thiamine hydrochloride as a catalyst in the absence of nitrogen atmosphere in a reasonably high yield. This method exclusively produces

Highly chemoselective deoxygenation of N-heterocyclic: N -oxides under transition metal-free conditions

Because their site-selective C-H functionalizations are now considered one of the most useful tools for synthesizing various N-heterocyclic compounds, the highly chemoselective deoxygenation of densely functionalized N-heterocyclic N-oxides has received much attention from the synthetic chemistry community. Here, we provide a protocol for the highly chemoselective deoxygenation of various functionalized N-oxides under visible light-mediated photoredox conditions with Na2-eosin Y as an organophotocatalyst. Mechanistic studies imply that the excited state of the organophotocatalyst is reductively quenched by Hantzsch esters. This operationally simple technique tolerates a wide range of functional groups and allows high-yield, multigram-scale deoxygenation. This journal is

HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compounds of the general formula (I), wherein Q is wherein the substituents of I, Ia and Ib are as defined in description and claims.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.